Prolastin Direct® Patient Services

One-Stop Prolastin Direct® Patient Services

Prolastin Direct® Patient Services is a unique medication delivery and health management service and more, which makes managing Alpha-1 easier.

Prolastin Direct® Patient Services enables you to directly receive PROLASTIN-C when and where you need it in the United States. Prolastin Direct® Patient Services reimbursement experts have a 99% success rate in gaining insurance authorization for therapy.1


Call Prolastin Direct® at 800-305-7881 with questions about insurance coverage, delivery of PROLASTIN-C and nursing services. Learn more about other options for help with insurance and co-pays.




How Prolastin Direct® works:

When your doctor prescribes PROLASTIN-C, you will automatically be enrolled in Prolastin Direct® Patient Services.

Prolastin Direct® Patient Services helps you get started on therapy and makes sure you get your therapy on time where you need it. Prolastin Direct® staff:

  • Coordinates authorization for therapy between your doctor and your insurance company
  • Calls you to see where and when you want to receive your infusions of PROLASTIN-C*
  • Makes arrangements for all nursing services and supplies
  • Arranges delivery of PROLASTIN-C to your home, your doctor's office, the infusion center at the local hospital, or any other location you choose
  • Makes sure your Prolastin Direct® case manager arranges for nursing services and delivery of PROLASTIN-C to wherever you're staying if you happen to be traveling
  • Connects you with an AlphaNet Coordinator, to start you in the optional health management program

Coordinators from AlphaNet, who are Alpha patients themselves, will call you at least once a month, with your permission, to:

  • Offer education and support with information about the disease, therapy, life style changes and other health management services
  • Connect you to support groups and others with Alpha-1
  • Alert you about news & events in the Alpha-1 community

* The exact date, delivery, location, and amount of the first and subsequent shipments are dependent upon your doctor's orders insurance authorization.


Patients participating with Prolastin Direct® patient services do better than patients just on therapy without health management support

A clinical study of Alpha-1 showed that patients who received augmentation therapy, such as PROLASTIN-C, plus the health management services of Prolastin Direct® Patient Services, experienced 10% fewer exacerbations compared with patients who received augmentation therapy alone.1


PROLASTIN®-C (alpha1-proteinase inhibitor [human]) is indicated for chronic augmentation and maintenance therapy in adults with clinical evidence of emphysema due to severe hereditary deficiency of alpha1-PI (alpha1-antitrypsin deficiency).

The effect of augmentation therapy with any alpha1-proteinase inhibitor (alpha1-PI), including PROLASTIN-C, on pulmonary exacerbations and on the progression of emphysema in alpha1-antitrypsin deficiency has not been conclusively demonstrated in randomized, controlled clinical trials. Clinical data demonstrating the long-term effects of chronic augmentation or maintenance therapy with PROLASTIN-C are not available.

PROLASTIN-C is not indicated as therapy for lung disease in patients in whom severe alpha1-PI deficiency has not been established.

PROLASTIN-C is contraindicated in IgA-deficient patients with antibodies against IgA due to the risk of severe hypersensitivity and in patients with a history of anaphylaxis or other severe systemic reactions to alpha1-PI.

Hypersensitivity reactions, including anaphylaxis, may occur. Monitor vital signs and observe the patient carefully throughout the infusion. Should hypersensitivity symptoms be observed, promptly stop infusion and begin appropriate therapy. Have epinephrine and other appropriate therapy available for the treatment of any acute anaphylactic or anaphylactoid reaction.

PROLASTIN-C may contain trace amounts of IgA. Patients with known antibodies to IgA, which can be present in patients with selective or severe IgA deficiency, have a greater risk of developing potentially severe hypersensitivity and anaphylactic reactions.

The most common drug-related adverse reaction observed at a rate of >5% in subjects receiving PROLASTIN-C was upper respiratory tract infection. The most serious adverse reaction observed during clinical trials with PROLASTIN-C was an abdominal and extremity rash in 1 subject.

Because PROLASTIN-C is made from human plasma, it may carry a risk of transmitting infectious agents, eg, viruses, the variant Creutzfeldt-Jakob disease (vCJD) agent, and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent. This also applies to unknown or emerging viruses and other pathogens.

Please click here for full Prescribing Information for PROLASTIN-C.


References

  1. Data on file. Life Science Services.